Continue Reading Below
Pfizer showered investors with a number of positive announcements during the month that helped to nudge its stock higher. Here's a review of the most important announcements from the period:
- Top-line results from a study comparing its rheumatoid arthritisdrug Xeljanz to AbbVie's Humira showed that Xeljanz in combination with methotrexate met its primary endpointin demonstrating non-inferiority versus Humira in combination withmethotrexate.
- Pfizer and partnerCelltrion Healthcare presented dataat the annual Congress of the European Crohn's and Colitis Organisation. The data showed that Inflectra -- Pfizer's biosimilar version of Johnson & Johnson's megablockbuster drug Remicade --showed similar efficacy and safety in treating Crohn's disease when compared toRemicade.
- Its FDA Biologics License Application, or BLA, for inotuzumab ozogamicin has been accepted for review. This drug has been granted Priority Review by the agency as a treatment for relapsed or refractory B-cell precursor acute lymphoblastic leukemia. A decision date is expected by August 2017.
- According to Pfizer and partner Merck, a second BLA has been accepted by the FDAfor Priority Review of avelumab as a hopeful treatment forurothelial carcinoma. A decision is also expected in August of this year.
Image source: Getty Images.
Continue Reading Below
When you add this string of positive developments to the general rise in the healthcare sector -- as measured by the Vanguard Health Care ETF-- it is easy to understand why shares rallied in February.
Pfizer's management team is projecting that 2017 will be another year of growth. Revenue is expected to land between $52 billion and $54 billion while adjusted earnings per share is forecasted to fall in the range of $2.50 to $2.60. While the midpoint of this range represents a small bump from the $52.8 billion in revenue and $2.40 in adjusted profits recorded in 2016, it's growth nonetheless. It's also worth pointing out that this forecast reflects the upcoming disposition of its Hospira Infusion Systems business and a negative hit from currencies. Absent these charges, the growth rates would be quite a bit higher.
All in all,Pfizer continues to look well positioned to post modest EPS growth in the years ahead. With shares trading for less than 14 times full-year earnings estimates and offering up a dividend yield of 3.7%, Pfizer remains a solid choice for healthcare investors who eschew risk.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of February 6, 2017